NEW YORK (TheStreet) -- CHANGE IN RATINGS
rated new Hold at Deutsche Bank. $57 price target. Do not expect a positive phase-3 trial for Dmab bone drug.
downgraded at FBR from Outperform to Market Perform. $6.75 price target. Supply-chain inventories are building up faster.
rated new Hold at Deutsche Bank. $57 price target. Company is facing potential new competition.
upgraded at BMO to Outperform. Valuation call, based on a $30 price target.
reinstated at BofA/Merrill with a Buy rating and $17 price target. Long term growth story driven by expansion projects and its utilities.
rated new Buy at Deutsche Bank. $44 price target. Provenge supply overhang should soon be removed, and the company has large potential to grow in Europe.
upgraded at Wells to Outperform. Valuation call, as the stock is down 30% year-to-date.
The Geo Group
reinstated at Barclays with an Overweight rating and $26 price target. CRN merger adds scale and inventory at a good price.
rated new Buy at Deutsche Bank. $42 price target. At least one of the company's HIV drugs in the pipeline should come to market.
upgraded at Credit Suisse to Outperform from Neutral. Valuation call. Fundamentals remain best in class. Maintain $125 price target.
downgraded at ThinkEquity from Buy to Hold. $27 price target. Don't see much growth potential from current games and margins could come under pressure.
upgraded at ThinkEquity from Hold to Buy. $90 price target. Growth in the virtualization business should continue to accelerate.
STOCK COMMENTS / EPS CHANGES
target cut at Jefferies. BRCD target was reduced to $6. OEM inventory correction could lead to lumpy results. Hold rating.
target upped at Jefferies to $86. Company should report a good quarter and currency trends have been improving. Hold rating.
estimates lowered at Morgan Stanley. CTAS estimates were cut through 2013. Company is facing increased competition. Equal-weight rating and $27 price target.
Corrections Corp of America
price target raised at Barclays by a dollar to $26 on solid 2011 guidance. Maintain Overweight rating.
estimates, target raised at Citigroup. Shares of DE now seen reaching $75. Estimates also increased, as commodity prices and costs are working in the company's favor. Buy rating.
numbers reduced at Susquehanna through 2012. Company is seeing lower sales, especially at Chili's. Positive rating and new $19 price target.
ITT Educational Services
price target cut at Credit Suisse to $57 from $78. Increased concerns about potential Gainful Employment exposure. Maintain neutral rating.
numbers cut at Citigroup. IART estimates were lowered through 2011. Company is facing higher interest expenses. Hold rating and new $41 price target.
estimates, target lowered at Sterne Agee. Shares of INTC now seen reaching $24. Estimates also cut, as lower consumer spending is hurting PC sales. Buy rating.
estimates, target reduced at Jefferies. Shares of INTU now seen reaching $44. Estimates also cut, given lower expected small-business growth. Buy rating.
numbers lowered at Citigroup. JCP estimates were cut through 2012. Company reduced its forward guidance. Buy rating and new $30 price target.
estimates boosted at Barclays. LBTYA 2010 and 2011 EPS estimates raised to -$5.05 and -$0.41, respectively. EBITDA growth and stable capex fund aggressive returns. Maintain Overweight rating.
Las Vegas Sands
price target higher at BofA/Merrill. LVS price target raised to $34 from $31 on robust 2Q results. Reiterate Buy rating.
target boosted at Deutsche. Shares of MON now seen reaching $70. Company is receiving positive feedback on its revamped pricing strategies. Buy rating.
estimates, target reduced at Citigroup. Shares of NVDA now seen reaching $12.50. Estimates also lowered, Macro environment is slowing and the company will soon face more graphics chip competition. Buy rating.
target lowered at Canaccord. OTEX target was reduced to $48. Becoming more cautious on potential growth, heading into the second half of the year. Hold rating.
Research in Motion
estimates increased at Citigroup through 2012. Buyback program should add to earnings. Sell rating and $50 price target.
This article was written by a staff member of TheStreet.